Stockage sous chaîne du froid pour les médicaments à base d’ARN 2025: Sauvegarder l’ARNm & Thérapies siARN
Cold Chain Storage for RNA Based Drugs: How to Safeguard mRNA and siRNA Therapies? Updated in November 2025. The rapid expansion of messenger RNA (ARNm) and small interfering RNA (siRNA) therapeutics offers transformative treatments for cancer, rare diseases and pandemics. Yet these fragile molecules degrade quickly when they wander outside precise temperature ranges. PfizerBioNTech’s vaccine initially required storage at about −80 °C (−112 °F), while Moderna’s mRNA vaccine needs −20 °C and remains viable for up to six months. Par contre, Onpattro, the first approved siRNA drug, stays potent for three years at 2–8 °C. In this guide you’ll discover how ultracold storage, controlled freeze–thaw cycles and emerging technologies protect RNAbased medicines—and how these strategies apply to your operations. Together we’ll explore market trends, sustainability initiatives and actionable tips for ensuring that every dose arrives safe and effective. What temperature ranges do mRNA, siRNA and gene therapies require? A detailed look at ultracold, frozen and refrigerated storage categories for different RNA products. How can controlled freezing, thawing and...